Argentina · Delayed Price · Currency is ARS Checkpoint Therapeutics Statistics
Total Valuation
Merck & Co. has a market cap or net worth of ARS 265.44 trillion. The enterprise value is 298.65 trillion.
| Market Cap | 265.44T |
| Enterprise Value | 298.65T |
Important Dates
The last earnings date was Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.77% |
| Shares Change (QoQ) | -0.71% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.51B |
Valuation Ratios
The trailing PE ratio is 13.58 and the forward PE ratio is 8.96.
| PE Ratio | 13.58 |
| Forward PE | 8.96 |
| PS Ratio | 3.50 |
| PB Ratio | 4.60 |
| P/TBV Ratio | 20.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 15.28 |
| EV / Sales | 3.63 |
| EV / EBITDA | 7.83 |
| EV / EBIT | 9.32 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.18 |
| Debt / FCF | n/a |
| Interest Coverage | 19.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.81% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 1.02B |
| Profits Per Employee | 264.20M |
| Employee Count | 75,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Merck & Co. has paid 3.27 trillion in taxes.
| Income Tax | 3.27T |
| Effective Tax Rate | 14.32% |
Stock Price Statistics
The stock price has decreased by -26.33% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -26.33% |
| 50-Day Moving Average | 19,724.00 |
| 200-Day Moving Average | 21,781.38 |
| Relative Strength Index (RSI) | 64.03 |
| Average Volume (20 Days) | 7,616 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.91 |
Income Statement
In the last 12 months, Merck & Co. had revenue of ARS 75.81 trillion and earned 19.55 trillion in profits. Earnings per share was 7,728.34.
| Revenue | 75.81T |
| Gross Profit | 58.90T |
| Operating Income | 29.53T |
| Pretax Income | 22.84T |
| Net Income | 19.55T |
| EBITDA | 34.75T |
| EBIT | 29.53T |
| Earnings Per Share (EPS) | 7,728.34 |
Balance Sheet
The company has 11.00 trillion in cash and 41.52 trillion in debt, giving a net cash position of -30,526.59 billion.
| Cash & Cash Equivalents | 11.00T |
| Total Debt | 41.52T |
| Net Cash | -30,526.59B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 57.68T |
| Book Value Per Share | 22,893.06 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 77.70%, with operating and profit margins of 38.95% and 25.79%.
| Gross Margin | 77.70% |
| Operating Margin | 38.95% |
| Pretax Margin | 30.12% |
| Profit Margin | 25.79% |
| EBITDA Margin | 45.83% |
| EBIT Margin | 38.95% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 435.90, which amounts to a dividend yield of 2.03%.
| Dividend Per Share | 435.90 |
| Dividend Yield | 2.03% |
| Dividend Growth (YoY) | 53.18% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.77% |
| Shareholder Yield | 2.80% |
| Earnings Yield | 7.37% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |